1. Prognostic Relevance of Papillary Muscle Infarction in Reperfused Infarction as Visualized by Cardiovascular Magnetic Resonance
- Author
-
Bernward Lauer, Matthias Gutberlet, Ingo Eitel, Sebastian Kerber, Holger Thiele, Gerhard Schuler, Johannes Schwab, Rainer Zimmermann, Matthias Pauschinger, Suzanne de Waha, Meinhard Mende, Steffen Desch, Ralf Birkemeyer, Dörthe Gehmlich, Omran Amer, and Jochen Wöhrle
- Subjects
Male ,medicine.medical_specialty ,Abciximab ,Myocardial Infarction ,Magnetic Resonance Imaging, Cine ,Infarction ,Immunoglobulin Fab Fragments ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,In patient ,Prospective Studies ,Myocardial infarction ,Papillary muscle ,Aged ,medicine.diagnostic_test ,business.industry ,Antibodies, Monoclonal ,Magnetic resonance imaging ,Middle Aged ,Papillary Muscles ,Prognosis ,medicine.disease ,Coronary Vessels ,medicine.anatomical_structure ,Injections, Intra-Arterial ,Echocardiography ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
Background— The prognostic significance of papillary muscle infarction (PapMI) on hard clinical outcomes has not been investigated in patients with reperfused ST-segment–elevation myocardial infarction. Noninvasive investigation by gadolinium-enhanced cardiac MRI enables the detection of PapMI with high spatial resolution. The aim of our study was (1) to assess the incidence, determinants, and clinical characteristics of PapMI in a large multicenter cohort of patients with ST-segment–elevation myocardial infarction and (2) to assess the prognostic significance of PapMI at 1-year follow-up. Methods and Results— We enrolled 738 patients with ST-segment–elevation myocardial infarction reperfused by primary angioplasty (P P P P =0.02). Patients with PapMI had a significantly higher mortality (8 [7.7%] versus 12 [1.9%]) and major adverse cardiac events (21 [20.2%] versus 31 [4.9%]) rate at 12-month follow-up ( P P Conclusions— The presence of PapMI is associated with decreased myocardial salvage, larger infarcts, and more pronounced reperfusion injury with subsequent significantly increased major adverse cardiac event rates. Consequently, our data underscore the importance of PapMI as a marker of poor outcome in patients with ST-segment–elevation myocardial infarction. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00712101.
- Published
- 2013